CIK 0001260990
ONCT Oncternal Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 24, 2024.
In brief
Oncternal Therapeutics, Inc. (ONCT) has 50 SEC Form 4 filings on file from 15 insiders, the latest filed on Jun 24, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
9 open-market trades have been scored at ONCT. The newest: Robert James Wills (director) bought $28k of stock on Apr 8, 2024, filed Apr 10, 2024, scored 31 (weak). The largest of the 9 shown: Robert James Wills (director) bought $59k on Mar 28, 2024, scored 30 (weak). 4 insiders bought within 14 days of each other around Apr 13, 2023.
1 Form 144 notice of planned sales is on file, the latest filed Oct 15, 2024.
Last 90 days
Signals
Open-market buys and sells at Oncternal Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Robert James Wills director buy | $28k 3,086 shares | +45% | - | |
| 30Weak | Robert James Wills director buy | $59k 6,914 shares | - | - | |
| 23Weak | David F Hale director buy | $8,859 980 shares | - | - | |
| 35Weak | Robert James Wills director sell | $8,859 980 shares | -100% | - | |
| 21Weak | Gunnar F. Kaufmann Chief Scientific Officer buy | $9,824 28,000 shares | +42% | - | |
| 56Moderate | James B Breitmeyer Chief Executive Officer buy | $44k 150,000 shares | +322% | - | |
| 36Weak | Chase C. Leavitt General Counsel/Secretary buy | $7,250 25,000 shares | +31% | - | |
| 43Moderate | Richard G Vincent Chief Financial Officer buy | $8,961 30,000 shares | +24% | - | |
| 33Weak | Salim Yazji Chief Medical Officer buy | $7,200 25,000 shares | +18% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 15, 2024 | Yazji Salim Officer | 4,681 0.16% of outstanding | $5,009 | Oct 14, 2024 | $1,960 |
Transactions
The newest 50 of 63 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2024 | William R Larue director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Jill DeSimone director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Daniel L Kisner director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Robert James Wills director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Michael G Carter director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Rosemary Mazanet director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | Charles Theuer director | AGrant or award Stock Optionsderivative | +2,200 | $0.00 | $0 | 2,200 | Jun 24, 2024 |
| Jun 20, 2024 | David F Hale director | AGrant or award Stock Optionsderivative | +3,300 | $0.00 | $0 | 3,300 | Jun 24, 2024 |
| Apr 8, 2024 | Robert James Wills director | POpen-market purchase Common Stock | +3,086 | $8.96 | $28k | 10,000 | Apr 10, 2024 |
| Mar 28, 2024 | Robert James Wills director | POpen-market purchase Common Stock | +6,914 | $8.48 | $59k | 6,914 | Apr 1, 2024 |
| Feb 23, 2024 | David F Hale director | POpen-market purchase Common Stock | +714 | $9.04 | $6,455 | 714 | Feb 27, 2024 |
| Feb 23, 2024 | Robert James Wills director | SOpen-market sale Common Stock | -980 | $9.04 | $8,859 | 0 | Feb 27, 2024 |
| Feb 23, 2024 | David F Hale director | POpen-market purchase Common Stockindirect: By Hale BioPharma Ventures, LLC | +266 | $9.04 | $2,405 | 29,673 | Feb 27, 2024 |
| Feb 14, 2024 | Rajesh Krishnan CTO/CSO | AGrant or award Stock Optionderivative | +17,700 | $0.00 | $0 | 17,700 | Feb 15, 2024 |
| Feb 14, 2024 | Chase C. Leavitt General Counsel/Secretary | AGrant or award Stock Optionderivative | +14,200 | $0.00 | $0 | 14,200 | Feb 15, 2024 |
| Feb 14, 2024 | Richard G Vincent Chief Financial Officer | AGrant or award Stock Optionderivative | +14,200 | $0.00 | $0 | 14,200 | Feb 15, 2024 |
| Feb 14, 2024 | Salim Yazji Chief Medical Officer | AGrant or award Stock Optionderivative | +14,200 | $0.00 | $0 | 14,200 | Feb 15, 2024 |
| Feb 14, 2024 | James B Breitmeyer Chief Executive Officer | AGrant or award Stock Optionderivative | +28,400 | $0.00 | $0 | 28,400 | Feb 15, 2024 |
| Feb 14, 2024 | James B Breitmeyer Chief Executive Officer | AGrant or award Stock Optionderivativeindirect: By Spouse | +6,200 | $0.00 | $0 | 6,200 | Feb 15, 2024 |
| Jan 3, 2024 | James B Breitmeyer Chief Executive Officer | FTax withholding Common Stock | -50,955 | $0.50 | $25k | 443,034 | Jan 5, 2024 |
| Jan 3, 2024 | Rajesh Krishnan Chief Technical Officer | FTax withholding Common Stock | -11,838 | $0.50 | $5,873 | 44,019 | Jan 5, 2024 |
| Jan 3, 2024 | Chase C. Leavitt General Counsel/Secretary | FTax withholding Common Stock | -11,838 | $0.50 | $5,873 | 84,758 | Jan 5, 2024 |
| Jan 3, 2024 | Richard G Vincent Chief Financial Officer | FTax withholding Common Stock | -8,868 | $0.50 | $4,399 | 140,922 | Jan 5, 2024 |
| Jan 3, 2024 | Salim Yazji Chief Medical Officer | FTax withholding Common Stock | -19,742 | $0.50 | $9,794 | 128,635 | Jan 5, 2024 |
| Jan 3, 2024 | James B Breitmeyer Chief Executive Officer | FTax withholding Common Stockindirect: By Spouse | -4,485 | $0.50 | $2,225 | 15,426 | Jan 5, 2024 |
| Jul 3, 2023 | James B Breitmeyer Chief Executive Officer | FTax withholding Common Stock | -47,992 | $0.36 | $17k | 493,989 | Jul 5, 2023 |
| Jul 3, 2023 | James B Breitmeyer Chief Executive Officer | FTax withholding Common Stockindirect: By Spouse | -4,007 | $0.36 | $1,443 | 19,911 | Jul 5, 2023 |
| Jun 28, 2023 | William R Larue director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Rosemary Mazanet director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Xin Nakanishi director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Robert James Wills director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Charles Theuer director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Michael G Carter director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | Jill DeSimone director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 28, 2023 | David F Hale director | AGrant or award Stock Optionsderivative | +37,500 | $0.00 | $0 | 37,500 | Jun 30, 2023 |
| Jun 28, 2023 | Daniel L Kisner director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 30, 2023 |
| Jun 12, 2023 | Gunnar F. Kaufmann Chief Scientific Officer | POpen-market purchase Common Stock | +25,000 | $0.35 | $8,745 | 91,726 | Jun 14, 2023 |
| Jun 14, 2023 | Gunnar F. Kaufmann Chief Scientific Officer | POpen-market purchase Common Stock | +3,000 | $0.36 | $1,079 | 94,726 | Jun 14, 2023 |
| Apr 13, 2023 | James B Breitmeyer Chief Executive Officer | POpen-market purchase Common Stockindirect: By Family Trust | +100,000 | $0.29 | $29k | 146,544 | Apr 17, 2023 |
| Apr 14, 2023 | James B Breitmeyer Chief Executive Officer | POpen-market purchase Common Stockindirect: By Family Trust | +47,750 | $0.30 | $14k | 194,294 | Apr 17, 2023 |
| Apr 14, 2023 | James B Breitmeyer Chief Executive Officer | POpen-market purchase Common Stockindirect: By Family Trust | +2,250 | $0.29 | $653 | 196,544 | Apr 17, 2023 |
| Apr 13, 2023 | Richard G Vincent Chief Financial Officer | POpen-market purchase Common Stock | +30,000 | $0.30 | $8,961 | 156,859 | Apr 14, 2023 |
| Apr 12, 2023 | Chase C. Leavitt General Counsel/Secretary | POpen-market purchase Common Stock | +15,000 | $0.29 | $4,350 | 96,901 | Apr 14, 2023 |
| Apr 12, 2023 | Salim Yazji Chief Medical Officer | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,850 | 149,676 | Apr 14, 2023 |
| Apr 13, 2023 | Chase C. Leavitt General Counsel/Secretary | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,900 | 106,901 | Apr 14, 2023 |
| Apr 13, 2023 | Salim Yazji Chief Medical Officer | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,850 | 159,676 | Apr 14, 2023 |
| Apr 14, 2023 | Salim Yazji Chief Medical Officer | POpen-market purchase Common Stock | +5,000 | $0.30 | $1,500 | 164,676 | Apr 14, 2023 |
| Feb 21, 2023 | James B Breitmeyer Chief Executive Officer | AGrant or award Stock Optionderivative | +650,000 | $0.00 | $0 | 650,000 | Feb 24, 2023 |
| Feb 21, 2023 | James B Breitmeyer Chief Executive Officer | AGrant or award Stock Optionderivativeindirect: By Spouse | +65,000 | $0.00 | $0 | 65,000 | Feb 24, 2023 |
| Feb 21, 2023 | James B Breitmeyer Chief Executive Officer | AGrant or award Stock Optionderivative | +42,196 | $0.00 | $0 | 42,196 | Feb 24, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- James B BreitmeyerChief Executive Officer
- Michael G Carterdirector
- Jill DeSimonedirector
- David F Haledirector
- Daniel L Kisnerdirector
- Gunnar F. KaufmannChief Scientific Officer
- Rajesh KrishnanChief Technology Officer
- William R Laruedirector
- Chase C. LeavittGeneral Counsel/Secretary
- Rosemary Mazanetdirector, other, officer
- Xin Nakanishidirector
- Charles Theuerdirector, ceo, president, officer
- Richard G VincentChief Financial Officer
- Robert James Willsdirector
- Salim YazjiChief Medical Officer
Questions about ONCT
Answered from the filings on this page, as of the latest one.
Are insiders buying ONCT?
No. In the last 90 days no insider at Oncternal Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ONCT on the open market?
Robert James Wills (director) bought $28k of ONCT on Apr 8, 2024 and filed the Form 4 on Apr 10, 2024. InsiderTell scored 31 (weak).
How many insiders file Form 4 at Oncternal Therapeutics, Inc.?
15 people have filed a Form 4 at Oncternal Therapeutics, Inc., among them James B Breitmeyer (Chief Executive Officer), Michael G Carter (director), Jill DeSimone (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.